Contact
R&D-Biopharmaceuticals GmbH
Am Klopferspitz 19
D-
82152 Planegg
Dr. Wolfgang Richter
Telefon: +49/89/70076490
E-Mail: wolfgang.richter@rdbiopharma.de
R&D News
Tubulysins / Cytolysins
The recently discovered natural product class of the tubulysins show a very high cytotoxic activity against in vitro and in vivo tumour models, especially against resistant tumour cell lines. >> more
Epothilones
The FDA approved the first epothilone drug (IXEMPRA™) for BMS in October 2007. Further drug candidates of this natural products class are currently investigated in several clinical trials by several companies. >> more
R&D GmbH, Am Klopferspitz 19, D-82152 Planegg-Martinsried © 2010